Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one?

Nature Reviews Clinical Oncology volume 17, pages 455–456 (2020)Cite this article

Subjects

Mature results of the PROfound study demonstrate that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib prolongs progression-free survival compared with second-generation hormonal therapies in men with metastatic castration-resistant prostate cancer harbouring BRCA1, BRCA2 or ATM mutations. However, a closer look at the efficacy of olaparib on a gene-by-gene basis suggests that its activity is most pronounced in BRCA2-mutant prostate cancers and might not be equally active in all homologous recombination repair-deficient cancers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Antonarakis, E. S. A New molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer. Oncologist 24, 430–432 (2019).

    Article  Google Scholar 

  2. de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1911440 (2020).

    Article  PubMed  Google Scholar 

  3. Dhawan, M. et al. DNA repair deficiency is common in advanced prostate cancer: new therapeutic opportunities. Oncologist 21, 940–945 (2016).

    Article  CAS  Google Scholar 

  4. Abida, W. et al. Preliminary results from the TRITON2 study of rucaparib in patients with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann. Oncol. 30 (Suppl. 5), v325–v355 (2019).

    Google Scholar 

  5. Abida, W. et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase 2 TRITON2 study. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-0394 (2020).

    Article  PubMed  Google Scholar 

  6. Smith, M. R. et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD [abstract]. J. Clin. Oncol. 37 (Suppl. 7S), 202 (2019).

    Article  Google Scholar 

  7. de Bono, J. S. et al. TALAPRO-1: a phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC) — first interim analysis [abstract]. J. Clin. Oncol. 38 (Suppl. 6S), 119 (2020).

    Article  Google Scholar 

  8. Marshall, C. H. et al. Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations. Eur. Urol. 76, 452–458 (2019).

    Article  CAS  Google Scholar 

  9. Antonarakis, E. S. et al. CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precis. Oncol. 4, 370–381 (2020).

    Article  Google Scholar 

  10. Chung, J. H. et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis. Oncol. https://doi.org/10.1200/PO.18.00283 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The work of E.S.A. is partially supported by NIH grants P30CA006973 and R01CA238384-A1.

Author information

Authors and Affiliations

  1. Departments of Oncology and Urology, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MA, USA

    Emmanuel S. Antonarakis

Authors
  1. Emmanuel S. Antonarakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emmanuel S. Antonarakis.

Ethics declarations

Competing interests

E.S.A. is a paid consultant and/or advisor to Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Dendreon, Janssen, Merck, Pfizer and Sanofi; has received research funding (via his institution) from AstraZeneca, Bristol Myers-Squibb, Clovis, Dendreon, Genentech, Janssen, Johnson & Johnson, Merck, Novartis and Sanofi; and is the co-inventor of an AR-V7 biomarker technology that has been licensed to Qiagen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antonarakis, E.S. Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one?. Nat Rev Clin Oncol 17, 455–456 (2020). https://doi.org/10.1038/s41571-020-0395-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-020-0395-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer